Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.
A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.
AstraZeneca announced a bold plan to have zero carbon emissions from the company’s global operations within the next five years.
Abbott’s shares rose to an all-time high after the device maker beat Wall Street estimates for quarterly sales on higher demand for the company’s nutrition products and generic drugs.
As medical technology increases, so too does the availability of options for different biomedical applications.
Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors, and the early thinking on biotech is yes.
The U.S. Food and Drug Administration classified the recall of Abbott Laboratories’ CentriMag blood pumping system, following the death of a patient, as Class 1 or the most serious type of recall.
Medical device maker Stryker Corp. will buy smaller rival Wright Medical Group for about $4 billion in cash, expanding into the fast-growing business of implants for shoulders and wrists.
EVERSANA, a leading independent provider of commercial services to the life science industry, announced an agreement to acquire Canada-based Cornerstone Research Group Inc.